Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, including kidney and respiratory diseases, with a focus on new kidney therapies in areas with unmet medical needs. The Company pursues new product concepts and applies scientific knowledge to the discovery of products from early-stage development through to commercialisation. Its products are DMX-652 for Acute Kidney Injury and DMX-200 for Focal Segmental Glomerulosclerosis (FSGS). The Company operates in one segment, being investment in research and development of biopharmaceutical drugs.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
15
Stocks News & Analysis
stocks
Guzman Y Gomez’s outlook unchanged despite strong update
Strong quarter yet shares remain expensive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.40 | 28.60 | -0.32% |
| CAC 40 | 7,896.02 | 22.91 | 0.29% |
| DAX 40 | 25,216.04 | 82.57 | -0.33% |
| Dow JONES (US) | 51,621.48 | 48.62 | -0.09% |
| FTSE 100 | 10,774.84 | 49.98 | 0.47% |
| HKSE | 24,062.72 | 251.45 | -1.03% |
| NASDAQ | 26,692.87 | 511.51 | -1.88% |
| Nikkei 225 | 64,425.95 | 3,318.34 | -4.90% |
| NZX 50 Index | 13,832.80 | 72.41 | 0.53% |
| S&P 500 | 7,718.94 | 86.51 | -1.11% |
| S&P/ASX 200 | 8,719.70 | 8.20 | -0.09% |
| SSE Composite Index | 3,707.48 | 59.75 | -1.59% |